On this page
Nystatin
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Nystatin | 500000 [USP'U]/1 | 261178 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Polyene Antifungal [EPC] | EPC | All 12 members |
| Polyenes [CS] | CS | All 13 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 062506-001 | NYSTATIN | TABLET | NYSTATIN | Prescription | AA | RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — no known or suspected bioequivalence problems (conventional dosage forms)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 39 | Manufacturing (CMC) | Approved | August 30, 2001 | — |
| Supplement | 38 | Manufacturing (CMC) | Approved | July 7, 2000 | — |
| Supplement | 37 | Manufacturing (CMC) | Approved | December 21, 1999 | — |
| Supplement | 36 | Manufacturing (CMC) | Approved | March 9, 1998 | — |
| Supplement | 35 | Manufacturing (CMC) | Approved | August 19, 1997 | — |
| Supplement | 34 | Manufacturing (CMC) | Approved | June 5, 1997 | — |
| Supplement | 33 | Labeling | Approved | April 2, 1997 | — |
| Supplement | 30 | Manufacturing (CMC) | Approved | January 7, 1997 | — |
| Supplement | 32 | Manufacturing (CMC) | Approved | November 26, 1996 | — |
| Supplement | 31 | Manufacturing (CMC) | Approved | October 4, 1996 | — |
| Supplement | 29 | Manufacturing (CMC) | Approved | August 16, 1996 | — |
| Supplement | 28 | Manufacturing (CMC) | Approved | January 25, 1996 | — |
| Supplement | 27 | Manufacturing (CMC) | Approved | January 25, 1996 | — |
| Supplement | 26 | Manufacturing (CMC) | Approved | January 25, 1996 | — |
| Supplement | 24 | Manufacturing (CMC) | Approved | March 2, 1995 | — |
| Supplement | 25 | Manufacturing (CMC) | Approved | February 10, 1995 | — |
| Supplement | 23 | Labeling | Approved | February 9, 1994 | — |
| Supplement | 22 | Manufacturing (CMC) | Approved | January 14, 1994 | — |
| Supplement | 21 | Manufacturing (CMC) | Approved | January 14, 1994 | — |
| Supplement | 20 | Manufacturing (CMC) | Approved | January 14, 1994 | — |
| Supplement | 19 | Manufacturing (CMC) | Approved | January 14, 1994 | — |
| Supplement | 18 | Manufacturing (CMC) | Approved | January 14, 1994 | — |
| Supplement | 17 | Manufacturing (CMC) | Approved | January 14, 1994 | — |
| Supplement | 16 | Manufacturing (CMC) | Approved | December 3, 1993 | — |
| Supplement | 15 | Labeling | Approved | December 3, 1993 | — |
| Supplement | 14 | Manufacturing (CMC) | Approved | December 3, 1993 | — |
| Supplement | 8 | Manufacturing (CMC) | Approved | December 3, 1993 | — |
| Supplement | 13 | Manufacturing (CMC) | Approved | August 31, 1993 | — |
| Supplement | 12 | Manufacturing (CMC) | Approved | August 31, 1993 | — |
| Supplement | 11 | Manufacturing (CMC) | Approved | April 1, 1993 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | April 1, 1993 | — |
| Supplement | 9 | Manufacturing (CMC) | Approved | April 1, 1993 | — |
| Original application | 1 | Approved | January 16, 1984 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251217). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Nystatin tablets are intended for the treatment of non-esophageal mucus membrane gastrointestinal candidiasis.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION The usual therapeutic dosage is one to two tablets (500,000 to 1,000,000 units nystatin) three times daily. Treatment should generally be continued for at least 48 hours after clinical cure to prevent relapse.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Nystatin Tablets are contraindicated in patients with a history of hypersensitivity to any of their components.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported (see PRECAUTIONS, General ). Gastrointestinal Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances. Dermatologic Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely. Other Tachycardia, bronchospasm, facial swelling, and nonspecific myalgia have also been rarely reported. To report SUSPECTED ADVERSE REACTIONS contact AvKARE at 1-855-361-3993; email drugsafety@avkare.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Nystatin, USP is an antimycotic polyene antibiotic obtained from Streptomyces noursei . Its structural formula: C 47 H 75 NO 17 M.W. 926.13 Nystatin tablets, USP are for oral administration and contain 500,000 units of nystatin, USP per tablet. Nystatin tablets, USP contain the inactive ingredients: corn starch, confectioner sugar, dibasic calcium phosphate, FD&C yellow #6, FD&C red #40, FD&C blue #2, hydroxypropyl cellulose, hypromellose, microcrystalline cellulose, magnesium stearate, polyethylene glycol, polysorbate 80, talc and titanium dioxide. Chemical Structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (see CLINICAL PHARMACOLOGY, Pharmacokinetics ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Nystatin tablets USP, 500,000 units are round, convex, brown, film-coated tablet debossed with 93 on one side and 983 on the reverse and are packaged in bottles of 100 tablets (NDC 0093-0983-01). Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). Keep tightly closed. Keep this and all medications out of the reach of children. Manufactured In Canada By: Teva Canada Limited Toronto, Canada M1B 2K9 Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev. O 11/2022
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: NYSTATIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 42291-651-90 | 42291-651 | AvKARE | 90 TABLET, FILM COATED in 1 BOTTLE (42291-651-90) | January 20, 2014 |
| 62135-741-90 | 62135-741 | Chartwell RX, LLC | 90 TABLET, FILM COATED in 1 BOTTLE (62135-741-90) | August 8, 2023 |
| 0093-0983-01 | 0093-0983 | Teva Pharmaceuticals USA, Inc. | 100 TABLET, FILM COATED in 1 BOTTLE (0093-0983-01) | September 30, 1990 |
| 0093-0983-99 | 0093-0983 | Teva Pharmaceuticals USA, Inc. | 681818 TABLET, FILM COATED in 1 PAIL (0093-0983-99) | June 23, 2023 |
| 42291-651 | 42291-651 | AvKARE | — | January 20, 2014 |
| 62135-741 | 62135-741 | Chartwell RX, LLC | — | October 31, 2011 |
| 0093-0983 | 0093-0983 | Teva Pharmaceuticals USA, Inc. | — | September 30, 1990 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.